SAVA stock information

Sector:

Healthcare

Description:

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences, Inc. website

Current Price

$23.23

RSI

41.05

Market Capitalization:

760.8M

Beta:

0.567

Volume:

704,366

Analyst Target Price:

$ 98.8

Economiic Fair Price:

Earnings DateNovember 09, 2022

Report DateNovember 07, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash174.7M

Debt164000

EPS-0.822

Profit MarginN/A

Revenue Per Share TTM0

Return On Equity TTM-0.187

2021 Free Cash Flow

$ -52.4M

-814.98 %

2020 Free Cash Flow

$ -5.7M

-126.22 %

2019 Free Cash Flow

$ -2.5M

46.92 %

2018 Free Cash Flow

$ -4.8M

42.09 %

2017 Free Cash Flow

$ -8.2M

33.08 %

2016 Free Cash Flow

$ -12.3M

Cassava Sciences, Inc.(SAVA)